Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name FLT3 exon 15 ins
Gene Variant Detail

FLT3 exon 15 ins (gain of function - predicted)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06578247 Phase III Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Quizartinib Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (QuANTUM-WILD) Recruiting USA | SWE | ROU | POL | NOR | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS 8
NCT06317649 Phase II Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) Recruiting USA 1
NCT06824168 Phase II Quizartinib Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission Recruiting USA | BRA | AUS 2
NCT07228273 Phase II Cytarabine + Daunorubicin Cytarabine + Fludarabine + Idarubicin + Venetoclax Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia Not yet recruiting USA 0
NCT06504459 Phase II Cladribine + Cytarabine + Venetoclax Azacitidine + Venetoclax Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML Recruiting USA 0
NCT04385290 Phase Ib/II Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) Recruiting DEU 0
NCT07059975 Phase I Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Idarubicin + Venetoclax Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide Cytarabine + Hydrocortisone + Methotrexate UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Recruiting USA 0